Pegzilarginase

LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: This indication is approved under accelerated approval based on reduction of plasma arginine.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
LOARGYS is an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction.

What it is used for

This indication is approved under accelerated approval based on reduction of plasma arginine. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Side effects, and when to stop

The following adverse reactions are described below and elsewhere in the labeling:

Hypersensitivity Reactions.

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Pegzilarginase; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/pegzilarginase
APA 7th: sofidex. (2026, August 3). Pegzilarginase. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/pegzilarginase
AMA 11th: Pegzilarginase. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/pegzilarginase

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.